Trial Profile
The relationship between IL6 and the kinetics of the ApoB-containing Lipoproteins in people with chronic inflammatory joint disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2017
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Acronyms apoB Kinetics; KALIBRA
- 15 Sep 2017 Primary endpoint of change in fractional catabolic rate of LDL-associated apolipoprotein has been met, according to results published in the Annals of the Rheumatic Diseases.
- 15 Sep 2017 Results published in the Annals of the Rheumatic Diseases
- 12 Dec 2014 Planned End Date changed from 19 Apr 2015 to 11 Dec 2014 as reported by United Kingdom Clinical Research Network.